157 related articles for article (PubMed ID: 24727838)
1. Does rituximab help patients with primary Sjögren syndrome?
Ann Intern Med; 2014 Feb; 160(4):I-11. PubMed ID: 24727838
[No Abstract] [Full Text] [Related]
2. Summaries for patients. Does rituximab help patients with primary Sjögren syndrome?
Ann Intern Med; 2014 Feb; 160(4):I-11. PubMed ID: 25006621
[No Abstract] [Full Text] [Related]
3. Treatment of primary Sjögren syndrome with rituximab.
Faustman DL; Vivino FB; Carsons SE
Ann Intern Med; 2014 Sep; 161(5):376-7. PubMed ID: 25178574
[No Abstract] [Full Text] [Related]
4. Treatment of primary Sjögren syndrome with rituximab. In response.
Saraux A; Nowak E; Devauchelle-Pensec V
Ann Intern Med; 2014 Sep; 161(5):377-8. PubMed ID: 25178575
[No Abstract] [Full Text] [Related]
5. Rituximab modulates the expression of IL-22 in the salivary glands of patients with primary Sjogren's syndrome.
Ciccia F; Giardina A; Rizzo A; Guggino G; Cipriani P; Carubbi F; Giacomelli R; Triolo G
Ann Rheum Dis; 2013 May; 72(5):782-3. PubMed ID: 23264342
[No Abstract] [Full Text] [Related]
6. Complete remission of protein-losing gastroenteropathy associated with Sjögren's syndrome by B cell-targeted therapy with rituximab.
Uraoka Y; Tanigawa T; Watanabe K; Machida H; Okazaki H; Yamagami H; Watanabe K; Tominaga K; Watanabe T; Fujiwara Y; Arakawa T
Am J Gastroenterol; 2012 Aug; 107(8):1266-8. PubMed ID: 22859008
[No Abstract] [Full Text] [Related]
7. First report of improvement of coeliac disease in a patient with Sjögren's syndrome treated with rituximab.
Nikiphorou E; Hall FC
Rheumatology (Oxford); 2014 Oct; 53(10):1906-7. PubMed ID: 24729401
[No Abstract] [Full Text] [Related]
8. EULAR Sjogren's Syndrome Disease Activity Index (ESSDAI) is sensitive to show efficacy of rituximab treatment in a randomised controlled trial.
Moerman RV; Arends S; Meiners PM; Brouwer E; Spijkervet FK; Kroese FG; Vissink A; Bootsma H
Ann Rheum Dis; 2014 Feb; 73(2):472-4. PubMed ID: 23940214
[No Abstract] [Full Text] [Related]
9. Treatment of primary Sjögren syndrome with rituximab: a randomized trial.
Devauchelle-Pensec V; Mariette X; Jousse-Joulin S; Berthelot JM; Perdriger A; Puéchal X; Le Guern V; Sibilia J; Gottenberg JE; Chiche L; Hachulla E; Hatron PY; Goeb V; Hayem G; Morel J; Zarnitsky C; Dubost JJ; Pers JO; Nowak E; Saraux A
Ann Intern Med; 2014 Feb; 160(4):233-42. PubMed ID: 24727841
[TBL] [Abstract][Full Text] [Related]
10. Predominantly proinflammatory cytokines decrease after B cell depletion therapy in patients with primary Sjogren's syndrome.
Pollard RP; Abdulahad WH; Bootsma H; Meiners PM; Spijkervet FK; Huitema MG; Burgerhof JG; Vissink A; Kroese FG
Ann Rheum Dis; 2013 Dec; 72(12):2048-50. PubMed ID: 23864239
[No Abstract] [Full Text] [Related]
11. [B-cell depletion and primary Sjögren's syndrome: is there a role for rituximab?].
Atzeni F; Sarzi-Puttini P
Reumatismo; 2010; 62(2):87-8. PubMed ID: 20657883
[No Abstract] [Full Text] [Related]
12. Rituximab therapy for primary Sjögren's syndrome: an open-label clinical trial and mechanistic analysis.
St Clair EW; Levesque MC; Prak ET; Vivino FB; Alappatt CJ; Spychala ME; Wedgwood J; McNamara J; Moser Sivils KL; Fisher L; Cohen P;
Arthritis Rheum; 2013 Apr; 65(4):1097-106. PubMed ID: 23334994
[TBL] [Abstract][Full Text] [Related]
13. Treatment approaches in primary Sjogren syndrome.
Vissink A; Kallenberg CG; Bootsma H
JAMA; 2010 Nov; 304(18):2015-6; author reply 2016. PubMed ID: 21063008
[No Abstract] [Full Text] [Related]
14. Maintenance of rituximab treatment in a patient with primary Sjögren's syndrome.
Lehner GF; Brunner-Palka M; Rettenbacher T; Schmidauer R; Herold M
Rheumatology (Oxford); 2014 Jul; 53(7):1349-50. PubMed ID: 24446469
[No Abstract] [Full Text] [Related]
15. Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjögren's syndrome treated with rituximab.
Meiners PM; Arends S; Brouwer E; Spijkervet FK; Vissink A; Bootsma H
Ann Rheum Dis; 2012 Aug; 71(8):1297-302. PubMed ID: 22258489
[TBL] [Abstract][Full Text] [Related]
16. Rituximab in primary Sjögren's syndrome: a ten-year journey.
Carubbi F; Alunno A; Cipriani P; Bartoloni E; Ciccia F; Triolo G; Gerli R; Giacomelli R
Lupus; 2014 Nov; 23(13):1337-49. PubMed ID: 25096066
[TBL] [Abstract][Full Text] [Related]
17. Persistence of immunoglobulin-producing cells in parotid salivary glands of patients with primary Sjögren's syndrome after B cell depletion therapy.
Hamza N; Bootsma H; Yuvaraj S; Spijkervet FK; Haacke EA; Pollard RP; Visser A; Vissink A; Kallenberg CG; Kroese FG; Bos NA
Ann Rheum Dis; 2012 Nov; 71(11):1881-7. PubMed ID: 22615459
[TBL] [Abstract][Full Text] [Related]
18. Dramatic reversal of lymphocytic interstitial pneumonitis in Sjögren's syndrome with rituximab.
Swartz MA; Vivino FB
J Clin Rheumatol; 2011 Dec; 17(8):454. PubMed ID: 22126805
[No Abstract] [Full Text] [Related]
19. Sustained response to rituximab in a patient with Sjögren´s syndrome and severe refractory polyneuropathy.
Pertovaara M; Korpela M
Clin Exp Rheumatol; 2012; 30(5):808; author reply 809. PubMed ID: 22992382
[No Abstract] [Full Text] [Related]
20. Rituximab and lupus interstitial lung disease: friend or foe?
Efthimiou P; Kukar M; Hersh A
Int J Rheum Dis; 2011 Feb; 14(1):e3-4. PubMed ID: 21303472
[No Abstract] [Full Text] [Related]
[Next] [New Search]
